The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...
-
ICON reports fourth quarter and full year 2021 results
Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.
-
ICON issues financial guidance for full year 2022
Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.
-
ICON named best contract research organisation in latest string of awards and recognitions
ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe.
-
ICON releases environmental, social and governance report
ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.
-
ICON announces the expansion of its Accellacare Site Network
New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability.
-
ICON reports third quarter 2021 financial results
Quarter 3 adjusted revenue of $1,870.4 million representing a year on year increase of 167% or 165% on a constant currency basis.
-
Tánaiste announces multi-million euro R&D support of ICON to accelerate decentralised clinical trial technology
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants.
-
ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
-
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customer’s commercial success through the development of medicines and medical devices.
-
ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting
All resolutions at the ICON Extraordinary General Meeting held on June 15, 2021 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.
